119 related articles for article (PubMed ID: 33354373)
1. Ocrelizumab-Induced Severe Colitis.
Lee HH; Sritharan N; Bermingham D; Strey G
Case Rep Gastrointest Med; 2020; 2020():8858378. PubMed ID: 33354373
[TBL] [Abstract][Full Text] [Related]
2. Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis.
Barnes A; Hofmann D; Hall LA; Klebe S; Mountifield R
Ann Gastroenterol; 2021; 34(3):447-448. PubMed ID: 33948072
[TBL] [Abstract][Full Text] [Related]
3. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
[TBL] [Abstract][Full Text] [Related]
4. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.
Sorensen PS; Blinkenberg M
Ther Adv Neurol Disord; 2016 Jan; 9(1):44-52. PubMed ID: 26788130
[TBL] [Abstract][Full Text] [Related]
5. [Additional possible mechanisms of the action of ocrelizumab in multiple sclerosis on example of a case-report].
Boyko OV; Khoroshylova II; Petrov SV; Lush NY; Guseva ME; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(8. Vyp. 2):116-120. PubMed ID: 30160679
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab.
Florou D; Katsara M; Feehan J; Dardiotis E; Apostolopoulos V
Brain Sci; 2020 Oct; 10(10):. PubMed ID: 33092190
[TBL] [Abstract][Full Text] [Related]
7. Ocrelizumab for the treatment of multiple sclerosis.
Bigaut K; De Seze J; Collongues N
Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis.
Ciardi MR; Iannetta M; Zingaropoli MA; Salpini R; Aragri M; Annecca R; Pontecorvo S; Altieri M; Russo G; Svicher V; Mastroianni CM; Vullo V
Open Forum Infect Dis; 2019 Jan; 6(1):ofy356. PubMed ID: 30697576
[TBL] [Abstract][Full Text] [Related]
10. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
11. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X; Hauser SL; Kappos L; Arnold DL; Bar-Or A; Comi G; de Seze J; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Rammohan KW; Selmaj K; Traboulsee A; Sauter A; Masterman D; Fontoura P; Belachew S; Garren H; Mairon N; Chin P; Wolinsky JS;
N Engl J Med; 2017 Jan; 376(3):209-220. PubMed ID: 28002688
[TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
[TBL] [Abstract][Full Text] [Related]
13. Two cases of meningitis associated with ocrelizumab therapy.
Theriault M; Solomon AJ
Mult Scler Relat Disord; 2020 Feb; 38():101866. PubMed ID: 31821962
[TBL] [Abstract][Full Text] [Related]
14. [Ocrelizumab for treatment of multiple sclerosis].
Graf J; Albrecht P; Goebels N; Aktas O; Hartung HP
Nervenarzt; 2020 Aug; 91(8):722-734. PubMed ID: 32524163
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W;
Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293
[TBL] [Abstract][Full Text] [Related]
17. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
18. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol.
Dirks P; Zingler V; Leemhuis J; Berthold H; Hieke-Schulz S; Wormser D; Ziemssen T
BMC Neurol; 2020 Mar; 20(1):95. PubMed ID: 32171264
[TBL] [Abstract][Full Text] [Related]
19. Ocrelizumab: its efficacy and safety in multiple sclerosis.
Juanatey A; Blanco-Garcia L; Tellez N
Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
[TBL] [Abstract][Full Text] [Related]
20. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.
Hutas G
Curr Opin Investig Drugs; 2008 Nov; 9(11):1206-15. PubMed ID: 18951300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
